Table 3.
Unadjusted and covariate-adjusted PPSV23 vaccine effectiveness for the prevention of hospitalized PPSV23-serotype CAP.
| Cases n (%) |
Controls n (%) |
Unadjusted VE % (95% CI) |
Adjusted VE % (95% CI) |
p-Value | |
|---|---|---|---|---|---|
| Overall Cohort, n = 3866 | |||||
| Number | 336 | 3350 | 17% (−13 to 40%) | 14% (−17% to 39%) | 0.350 |
| PPSV23 vaccinated | 48 (8) | 560 (92) | |||
| Non-vaccinated | 288 (9) | 2790 (91) | |||
PPSV23: Pneumococcal polysaccharide vaccine; VE: Vaccine effectiveness. Cases: Patients hospitalized with CAP with positive urinary antigen detection for any of the 23 S. pneumoniae serotypes found in the PPSV23 vaccine. Controls: Patients hospitalized with CAP with negative urinary antigen detection for any of the 23 S. pneumoniae serotypes found in the PPSV23 vaccine.